To appraise the clinical and cost effectiveness of avatrombopag and lusutrombopag within their marketing authorisations for treating thrombocytopenia in people with chronic liver disease needing an elective procedure.
 
Status In progress
Process MTA
ID number 1520

Provisional Schedule

Committee meeting: 1 26 September 2019
Committee meeting: 2 26 November 2019
Expected publication 26 February 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Dova Pharmaceuticals (avatrombopag)
  Shionogi Inc (lusutrombopag)
Others Department of Health and Social Care
  NHS Coventry and Rugby CCG
  NHS England
  NHS Leeds North CCG
  Welsh Government
Patient carer groups Action on Addiction
  Addaction
  Addiction Today
  ADFAM
  Alcohol Concern
  British Liver Trust
  Compass UK
  Haemophilia Society
  Hepatitis B Foundation UK
  Hepatitis C Trust
  ITP Support Association
  Lifeline Project
  Liver4Life
  Muslim Council of Great Britain
  National Obesity Forum
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Turning Point
  Weight Concern
Professional groups Association of Surgeons of Great Britain and Ireland
  British Association for the Study of the Liver
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatric Society
  British Infection Society
  British Society of Gastroenterology
  British Society for Haematology
  British Viral Hepatitis Group
  Hepatitis Nurse Specialist Forum
  Haemophilia Nurses Association
  NHS Blood and Transplant
  Positive Prevention Plus
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  UK Clinical Pharmacy Association
  UK Clinical Virology Network
  UK Forum on Haemoglobin Disorders
  UK Haemophilia Centre Doctors’ Organisation
  UK Harm Reduction Alliance

Commentators

Associated public health groups Public Health England
  Public Health Wales
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Hepato-Biliary Group
  Cochrane Infectious Diseases group
  Foundation for Liver Research
  MRC Clinical Trials Unit
  National Institute for Health Research
  UK National Screening Committee

Timeline

Key events during the development of the guidance:

Date Update
28 December 2018 Invitation to participate
17 December 2018 In progress, This appraisal has been referred to NICE.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance